NCT03501134View on ClinicalTrials.gov

Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields

CompletedOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

August 8, 2018

Primary Completion Date

June 3, 2021

Study Completion Date

June 3, 2021

Conditions
Malignant Glioma
Interventions
DEVICE

NovoTTF

We are studying the effect of Tumor Treating Fields (NovoTTF), for example Optune™, on the quality of life, including exercise, sleep quality, and mood, of patients with malignant glioma who plan to use the NovoTTF device.

Trial Locations (1)

27710

The Preston Robert Tisch Brain Tumor Center at Duke, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
collaborator

NovoCure Ltd.

INDUSTRY

lead

Duke University

OTHER

NCT03501134 - Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields | Biotech Hunter | Biotech Hunter